Research programme: KAT6 inhibitors - Aurigene Oncology/Olema Pharmaceuticals
Latest Information Update: 17 Oct 2023
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology; Olema Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action KAT6A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 13 Oct 2023 Pharmacodynamics data from a preclinical trial in Cancer released by Olema Pharmaceuticals
- 11 Oct 2023 Pharmacokinetics and pharmacodynamics data from a preclinical studies in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 25 Sep 2023 Preclinical trials in Cancer in India (unspecified route), prior to August 2023